Explore WARF Inventions and Patents
WARF’s portfolio of more than 1,600 patented technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.
Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.
Visit our subscription center to sign up for our monthly email updates and learn when new WARF technologies become available for licensing.
The gene in C. elegans that encodes the enzyme is called RDE-3. Although its sequence was already known, its polymerase activity was not.
The new mutants show improved in vivo activity and more sustained therapeutic effect than naturally occurring Factor IX. They could potentially be administered intravenously, orally or by another route.
The copolymers include a polyhydroxamic acid-containing block and a polyferrocenyl block. They can be prepared by standard peptide synthesis or polymerization methods.
In the process, a suitable reagent is used to phosphorylate the flour’s lysine amino acid residues. The phosphorylated flour then is mixed with an oxidizing agent that drives the formation of cross-linking bonds. This improves the flour’s adhesive properties. Unwanted salts created in the process can be removed.
Flours of other legumes and/or oil seed crops (e.g., flax, canola) are suitable as well.
The inhibitors work by binding to a cell’s proteasome –the large complex of enzymes found in the cytoplasm that degrades and disposes old proteins. This binding action blocks chemotherapeutic agents from invading the cell nucleus.
To shield ovaries from chemotherapy toxicity, an effective dose of a proteasome inhibitor like bortezomib (Bort) or MG-132 is injected about an hour before treatment.